Subscribe

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

Completed Research: PRACTICE MANAGEMENT RESEARCH
Abstract #CR10

Knowledge Gaps and Educational Needs for Common Cancer Therapy–Related Cardiovascular Adverse Events and Related Drug Interactions

JHOP - March 2023 Vol 13 Special Feature - HOPA Abstracts

Presenter: Kristen T. Peterson, PharmD, BCOP, Duke University Medical Center

Co-Authors: Heather Moore, PharmD, BCOP, CPP, Duke University Medical Center, Durham, NC; Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPS, CACP, Baptist Health Systems–Kentucky and Indiana, Louisville, KY; Sarah Hayes, PharmD, BCOP, University of Minnesota Health Systems, Robbinsdale, MN; Israa Yaseen, BPharm, BCCP, BCPS, Bagdad Heart Center–Medical City, Bagdad, Iraq; Preston Skersick, PharmD, University of North Carolina Eshelman School of Pharmacy, Chapel Hill, NC; Kelsey Truitt, PharmD, University of North Carolina Eshelman School of Pharmacy, Chapel Hill, NC; Sarah Kaspari, PharmD, University of North Carolina Eshelman School of Pharmacy, Chapel Hill, NC; Stephen Casselli, PhD, International Cardio-Oncology Society, Tampa, FL; Jo E. Rodgers, PharmD, BCPS, BCCP, FCCP, FHFSA, FAHA, University of North Carolina Eshelman School of Pharmacy, Chapel Hill, NC

BACKGROUND: An unprecedented rise in the number of novel oncolytic agents has recently led to a substantial increase in the complexity of cancer management. The real-world use of these therapies has increased the awareness of cancer therapy–related cardiovascular toxicities (CTR-CVTs) and related drug–drug interactions (DDIs), warranting healthcare provider education.

OBJECTIVE: To obtain further insight into knowledge gaps and educational needs based on the frequency of observed CTR-CVTs and related DDIs and the perceived ease of their management.

METHOD: A 20-question survey was distributed to pharmacists and other healthcare providers using e-mail listservs of targeted professional organizations, including the International Cardio-Oncology Society and the Hematology/Oncology Pharmacy Association. The survey assessed background (eg, training, practice setting), CTR-CVTs, and the related DDIs encountered. In addition, the preferences for future educational topics were assessed.

RESULTS: Of 220 survey respondents (102 pharmacists and 118 other healthcare providers, >80% physicians), the majority reported being at academic medical centers (>60% academic, >30% community). Although pharmacists were predominately from North America (96%) and represented cardiology (49%) and oncology/hematology specialties (44%/28%), other healthcare providers were from more diverse regions (Europe, 36%; North America, 28%; South America/other, 25%) and primarily specialized in cardiology (86%). The cancer types varied greatly across all of the healthcare providers. Of 102 pharmacists, 89% were PharmD-trained, and 56% and 33% completed residency and board certification in cardiology or oncology, respectively. In all, 49% of the pharmacists specialized in cardiology and 44% specialized in oncology. The most common CTR-CVTs reported by pharmacists were cancer therapy–related cardiac dysfunction (77%), thromboembolic disease (71%), and hypertension (64%). The most common pharmacodynamic DDIs that were encountered were QT prolongation/torsades de pointes, thromboembolic disease, bleeding, and hypertension, whereas the pharmacokinetic DDIs were with oral anticoagulants, antiarrhythmic agents, and numerous oncolytic agents. The pharmacists reported the least comfort with managing ibrutinib- or other drug–associated bleeding and arsenic-associated QT prolongation, and the greatest comfort with managing anthracycline- or HER2-targeted therapy–associated cardiac dysfunction. Regarding the recommendations for future education, immune checkpoint inhibitor–associated myocarditis (70%), ibrutinib- or other drug–associated bleeding (61%), and atrial fibrillation (61%) were ranked of highest need. Similar survey results were observed with other healthcare providers.

CONCLUSION: This survey indicates that knowledge gaps exist for pharmacists and other healthcare providers for several CTR-CVTs and related DDIs. Future educational initiatives should target these specific areas.

Related Items
Clinical Pharmacist–Initiated Tyrosine Kinase Inhibitor Discontinuation in Patients with Chronic Myeloid Leukemia
JHOP - March 2023 Vol 13 Special Feature published on March 23, 2023 in HOPA Abstracts
Evaluation of Chemotherapy-Induced Myelosuppression in Patients with Extensive-Stage Small-Cell Lung Cancer Who Received Trilaciclib: Retrospective Analysis of Florida Community Oncology Practices
JHOP - March 2023 Vol 13 Special Feature published on March 23, 2023 in HOPA Abstracts
Evaluation of the Safety of the New Alcohol-Containing Formulation of Cyclophosphamide
JHOP - March 2023 Vol 13 Special Feature published on March 23, 2023 in HOPA Abstracts
Health System Specialty Pharmacy Integration Impact on Prescription Fill Time
JHOP - March 2023 Vol 13 Special Feature published on March 23, 2023 in HOPA Abstracts
Invasive Fungal Disease in Patients with Hematologic Malignancies Receiving Micafungin Prophylaxis
JHOP - March 2023 Vol 13 Special Feature published on March 23, 2023 in HOPA Abstracts
Multidisciplinary Approach in Maximizing Oncology Clinic Throughput in a Comprehensive Cancer Center
JHOP - March 2023 Vol 13 Special Feature published on March 23, 2023 in HOPA Abstracts
Optimization of Rasburicase Dose for the Management of Tumor Lysis Syndrome in Community Oncology Practices
JHOP - March 2023 Vol 13 Special Feature published on March 23, 2023 in HOPA Abstracts
Pharmacist-Led 14-Day Oncolytic Drug Check-In Protocol
JHOP - March 2023 Vol 13 Special Feature published on March 23, 2023 in HOPA Abstracts
Safety of Rapid Dose Escalation of Venetoclax in Patients with Hematologic Malignancies
JHOP - March 2023 Vol 13 Special Feature published on March 23, 2023 in HOPA Abstracts
Safety Outcomes of Oxaliplatin Rapid-Rate Infusion versus Standard-Rate Infusion
JHOP - March 2023 Vol 13 Special Feature published on March 23, 2023 in HOPA Abstracts
© Amplity Health. All rights reserved.